Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

Subjects:

Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

Effects of BM-MSCs on ROS generation in DCS rats. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs attenuates DCS induced lung inflammation. by Chen Lu (135200)

Subjects:

Isotype control overlays. by Chen Lu (135200)

Subjects:

Original uncropped blot. by Chen Lu (135200)

Subjects:

Characterization of BM-MSC. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Utilization of anticoagulants at eight hospitals from 2019 to 2023. by Wei Luo (80175)

Subjects:

Identification of BM-MSCs. by Chen Lu (135200)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects:

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Indications for warfarin prescription in outpatients and inpatients in 2023. by Wei Luo (80175)

Subjects:

Western blotting for OMP expression using olfactory bulb and olfactory epithelium. by Myeongguk Jeong (16386165)

Subjects:

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

Subjects:

Effects of BM-MSCs on different types of lung cell death in different group. by Chen Lu (135200)

Subjects:

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

A schematic representation of how BM-MSCs reduce inflammation, oxidative stress, and cell death to alleviate decompression induced acute lung injury. by Chen Lu (135200)

Subjects: